AbbVie buys $2.1bn Capstan, adding new in vivo CAR-T to pipeline
AbbVie gains control of an in vivo CAR-T therapy that could overcome limitations with currently approved autologous counterparts.

AbbVie gains control of an in vivo CAR-T therapy that could overcome limitations with currently approved autologous counterparts.
Lisata will utilise GATC's Multiomics Advanced Technology platform.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Juvenescence enhances AI drug discovery with Ro5 acquisition
Pharma’s AI prospects get nudged into the future with EU’s AI act
Next-generation targeting for evolving HCP engagement
Are regulators keeping pace with AI adoption in clinical trials?